NCT00091676 - Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma | Biotech Hunter

Enrollment

629

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Non-Hodgkins Lymphoma

Interventions

BIOLOGICAL

FNHLId1

5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4

BIOLOGICAL

KLH + GM-CSF

5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4